Chronic Lymphocytic Leukemia
Conditions
Brief summary
This is a phase II multicenter, non-comparative, open label study in older previously untreated Chronic Lymphocytic Leukaemia patients, requiring therapy, aimed at defining the efficacy profile (ORR, CRR and TTP) of pentostatin and cyclophosphamide given in combination with Ofatumumab (PCO).
Detailed description
Chronic lymphocytic leukemia (CLL) is the most common of the chronic lymphoid leukemias, comprising 30% of all adult leukemias. The majority of CLL patients are of advanced age. Currently, immunochemotherapy with Rituximab, Fludarabine and Cyclophosphamide (RFC) is the standard of care in previously untreated patients with CLL requiring treatment. The combination of Pentostatin and Cyclophosphamide has generated excellent clinical response rates in pretreated B-CLL patients. Early data on the use of Ofatumumab as a single agent in Fludarabine-refractory CLL patients have been reported. Given the reported efficacy of chemo-immunotherapy combinations in CLL and the promising activity and toxicity profile of Pentostatin combinations, we designed a trial of Pentostatin, Cyclophosphamide, and Ofatumumab for previously untreated older patients with CLL. The aim is improving efficacy, in Rituximab resistant CLL, and toxicity considering the good profile of tolerability showed using Ofatumumab as single agent.
Interventions
DRUGPentostatin
Lyophilized powder for intravenous administration.
DRUGCyclophosphamide
IV
DRUGOfatumumab
Liquid concentrate for solution for infusion.
Sponsors
Regione Lombardia
GlaxoSmithKline
Hospira, now a wholly owned subsidiary of Pfizer
Niguarda Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of B-CLL defined by: 1. Circulating lymphocytes of more than or equal to 5 x109/L B lymphocytes (5000/mL) in the peripheral blood for the duration of at least 3 months. AND 2. Flow cytometry confirmation of immunophenotype: CD5, CD19, CD20, CD23, CD79b, and surface Ig * Age ≥ 65 years * Active disease and indication for treatment based on modified NCI-WG guidelines defined by presenting at least any one of the following conditions: * Evidence of progressive marrow failure as manifested by development of, or worsening of anemia and/or thrombocytopenia * Massive (i.e. \> 6 cm below the left costal margin) or progressive or symptomatic splenomegaly * Massive nodes (i.e. \> 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy * Progressive lymphocytosis with an increase of \> 50% over a two month period or an lymphocyte doubling time \< 6 months * A minimum of any one of the following disease-related symptoms must be present: 1. Unintentional Weight loss ³ 10% within the previous six months 2. Fevers \> 38.0 °C for ≥ 2 weeks without evidence of infection 3. Night sweats for more than 1 month without evidence of infection * Not been previously treated for B-CLL (prior autoimmune hemolytic anemia treatment permitted) * ECOG Performance Status of 0-2 * Signed written informed consent prior to performing any study-specific procedures
Exclusion criteria
* Prior therapy for B-CLL with any agent except corticosteroids used to treat autoimmune hemolytic anemia * Active autoimmune hemolytic anemia (AIHA) requiring corticosteroid therapy \> 100 mg equivalent to hydrocortisone, or chemotherapy * Known Richter transformation * Known CNS involvement of B-CLL * Any radiation therapy ≤ 4 weeks prior to registration; * Any major surgery ≤ 4 weeks prior to registration; * Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis C * Past or current malignancy with the exception of basal cell carcinoma of the skin or in situ carcinoma of the cervix or the breast unless the tumor was successfully treated with curative intend at least 2 years prior to trial entry. * Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months prior to Visit 1, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities * History of significant cerebrovascular disease * Glucocorticoid unless given in doses ≤ 100 mg/day hydrocortisone (or equivalent dose of other glucocorticoid) if for exacerbations other than B-CLL (e.g. asthma) * Known HIV positive * Positive serology for Hepatitis B (HB), defined as a positive test for HBsAg. In addition if negative for HBsAg but HBcAb positive and HBsAb negative a HB DNA test will be performed and if positive the subject will be excluded. Note: if HBcAb positive and HBsAb positive, which is indicative of a past infection, the subject can be included. * Screening laboratory values: 1. Creatinine Clearance \< 60 mL/min 2. Total bilirubin \> 2.0 times upper normal limit (unless due to liver involvement of BCLL) 3. ALT \> 3.0 times upper normal limit (unless due to liver involvement of B-CLL) * Treatment with any non-marketed drug substance or experimental therapy within 4 weeks prior to Visit 1 or currently participating in any other interventional clinical study * Known or suspected inability to comply with the study protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | 2 months after the last dose received (End of treatment period) | To assess the overall response rate (ORR) using pentostatin, cyclophosphamide, and ofatumumab in patients with previously untreated CLL requiring therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response Rate (CRR) | Baseline, at cycle 3 and 2 months after the last dose received | To assess the complete response of CLL patients treated with pentostatin, cyclophosphamide, and ofatumumab |
| Minimal Residual Disease (MRD) | Every 3 months from the last dose of treatment up to 2 years follow up. | To determine the proportion of patients who achieve a minimal residual disease (MRD) negative state as assessed by flow cytometry.It will be assessed only in patients responding to PCO treatment. |
| Progression-Free Survival | Measured as the time from inclusion in the trial to disease progression or death, assessed up to 2 years | To determine the progression-free survival in CLL patients treated with pentostatin,cyclophosphamide, and ofatumumab. |
| Overall Survival (OS) | Measured as the time from inclusion in the trial until death from any cause, assessed up to 2 years of follow up | To assess overall survival (OS) of CLL patients treated with pentostatin, cyclophosphamide, and ofatumumab |
| Adverse Events according to CTCAE, Version 3.0 NCI CTCAE | From informed consent signed through to 28 days after the last study drug administration | To monitor and assess toxicity of pentostatin, cyclophosphamide, and ofatumumab in patients with previously untreated CLL. |
| Genetic analysis by Fish | Baseline, 2 months after the last dose received and at month 12 and 24 during follow up | To determine if cytogenetic abnormalities identified by FISH, relate to response to PCO therapy. |
| Ofatumumab pharmacokinetics parameter | Cycle1: Day 1, 2, 3, 8, 9, 15. Cycles 2-5: Day 1, 2, 3, 8,15. Cycle 6: Day 1, 2, 3, 8, 15, 21 | To assess ofatumumab pharmacokinetic parameters |
| IgVH mutation status | Baseline, 2 months after the last dose received and at month 12 and 24 during follow up | To determine if IgVH mutation status relate to response to PCO therapy |
| Time To Progression (TTP) | Measured as the time from inclusion in the trial until disease progression or death, assessed up to 2 years | To assess the time-to-progression (TTP) of CLL patients treated with pentostatin, cyclophosphamide, and ofatumumab |
Countries
Italy
Outcome results
None listed